Related Experiment Videos

Cell cycle independent infection and gene transfer by recombinant Sendai viruses

Sorin Armeanu1, Guy Ungerechts, Christian Bernloehr

  • 1Internal Medicine I, University Clinic Tübingen, D-72076, Tübingen, Germany.

Insights

Sendai viruses (SeV) efficiently infect cells regardless of their cell cycle phase, making them ideal for gene therapy. This viral vector system overcomes limitations of other vectors dependent on cell division for transduction.

Area of Science:

  • Virology
  • Gene Therapy
  • Cell Biology

Background:

  • Viral vector efficiency in somatic gene therapy often depends on the target cell's cycle phase.
  • Optimized viral vectors should transduce cells in all cell cycle phases equally.
  • Recombinant Sendai viruses (SeV) show potential for gene therapy due to broad tissue tropism.

Purpose of the Study:

  • To investigate the influence of cell cycle phases on Sendai virus (SeV) infection efficiency.
  • To evaluate SeV as a potential gene therapy vector for targeting cells in various cycle phases.
  • To compare SeV's cell cycle independence with other viral vectors.

Main Methods:

  • Synchronization of NIH 3T3 cells and contact inhibition of human fibroblasts were used to study cell cycle effects.
  • SeV infection rates were assessed in synchronized and non-synchronized cells.
  • Infection efficiency in target tissues (human umbilical cord cells, primary human hepatocytes) was evaluated.
  • The effect of aphidicolin (a DNA polymerase inhibitor causing G1/M arrest) on SeV and adenoviral vector infection was tested.

Main Results:

  • SeV infection rates were not negatively influenced by cell synchronization or contact inhibition.
  • SeV efficiently infected human umbilical cord derived cells and primary human hepatocytes.
  • Aphidicolin inhibited SeV infection but not adenoviral vector infection, suggesting a unique interaction with SeV replication.

Conclusions:

  • SeV based vector particles demonstrate equal transduction efficiency across different cell cycle phases.
  • SeV is a promising candidate for gene therapy applications requiring broad cell targeting.
  • The differential effect of aphidicolin provides new insights into paramyxovirus cell cycle interactions.

Related Concept Videos